Vernillet, L.

cpt -11 -11 sequence cancer patient study cpt -113 cddp course pharmacokinetic 80 mg /m 200 mg /m infusion cisplatin phase level sn -38 dose level parameter administration 90- min i.v irinotecan phase i study topoisomerase i inhibitors -38 treatment value toxicity 60 mg /m cpt -11 lactone 175 mg /m metabolite difference combination liter -113 interaction clearance t test table verweij values sd analysis 3- h i.v 10 cancer patients dose-normalized pharmacokinetic parameters lactone 10 9/ liter plasma leukocyte tumor body clearance jonge sparreboom pharmacodynamic topotecan phase i platinum grade 3 neutrophil count oncol concentration influence count dose-normalized metabolism decrease schedule stoter dna-adduct model 1/2 effect drug administration agent non-small-cell lung cancer topoisomerase inhibitor limit sequence dependence compartmental analysis